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SUMMARY – The treatment of multiple sclerosis (MS) is becoming more complex, especially 
with the expanding number of available therapies for relapsing forms of MS. Greater understand-
ing of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new 
treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) 
used in MS treatment have shown only partial benefits in controlling disease progression, primarily 
by reducing the inflammation component. However, new therapies for MS have been shown to be 
effective in delaying disease progression by protecting against brain atrophy, which is considered 
the most important preindicator of future patient disability. The favorable effect on reducing brain 
atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, 
marking progress in the treatment of MS.
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The Risk of Multiple Sclerosis
If left untreated, multiple sclerosis (MS) is a dev-
astating disease with multiple negative impacts on 
patient health. If we consider that quality of life is a 
multidimensional category comprised of functional, 
emotional, social and spiritual elements of health, it 
is evident that the negative impacts of MS are mani-
fested in all aspects of the patient’s quality of life 
(Fig. 1).
Some indicators of the negative impacts of MS on 
the quality of life pertain to increased unemployment, 
divorce and solitary life, and suicide. Life expectancy 
of an untreated MS patient is by about 8 years shorter 
than of persons without MS. The quality of life of 
those suffering from MS is inversely proportionate to 
the Expanded Disability Status Scale (EDSS) score. 
Approximately 50% of MS patients become unem-
ployed when they reach an EDSS score of 3 and/or 
after 10 years of receiving the diagnosis1,2.
Multiple Sclerosis Pathogenesis: Is It an 
Inflammatory or Primarily Degenerative Disease? 
Multiple sclerosis is considered an autoimmune, 
demyelination and neurodegenerative disease of the 
central nervous system with a biphasic course that 
causes a wide spectrum of neurological and psycho-
logical symptoms.
The paradigm of the MS pathogenesis is still a 
topic of discussion and debate among controversial 
positions. The currently established stance in which 
MS is an autoimmune process led by an inflammatory 
demyelination disease counters the theory that MS is 
actually a neurodegenerative disease, either primary or 
associated with age4. Research has shown that there is 
support for both scenarios and that the ‘demyelination 
syndrome’ implies various types of damage, which 
suggests a range of mechanisms involved in their de-
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velopment. In addition to focal demyelination, MS is 
characteristic due to the diffuse appearance of damage 
to normal-appearing white matter (NAWM), axonal 
damage that can be of varying intensity, and brain 
atrophy5,6. The acute phase of the disease is marked 
by focal demyelination with post-contrast imbibitions, 
while the progressive phase of the disease is dominat-
ed by atrophy of the brain and loss of axons, which is 
correlated with the degree of neurological disability.
The relapsing-remitting form of MS (RRMS) is 
classically considered a biphasic disease with relapses 
of a potentially reversible phase of the disease, corre-
lated with inflammatory demyelination and a second-
ary potentially irreversible phase of the disease that is 
marked by critical axon loss. Inflammatory changes 
are less pronounced in the later phases, although the 
disease shows increasing progression. This dissocia-
tion between the intensity of inflammation and the 
progressive development of neurological disability 
represents the inflammatory-neurodegenerative par-
adox that is characteristic of MS, and which marks 
transition to the irreversible phase of the disease. Nu-
merous clinical, neuropathological and neuroimaging 
studies have aimed to define mutual associations of 
the inflammatory and progressive phases of MS. It has 
long been known that early relapse impacts the long 
term disability in MS7, although there are still uncer-
tainties and ambiguities as to the trigger that switches 
RRMS to the secondary progressive form. Some epi-
demiological studies of the natural course of MS have 
shown certain limitations regarding the effects of the 
inflammatory phase of the disease on the progression 
of disability, giving a conclusion that the relapsing 
and neurodegenerative phases of MS are mutually in-
dependent. In such a case, not only the number of re-
lapses can have predictive value in the development of 
disability; age, sex, residual deficit after first relapse, 
time to second relapse, total number of relapses in the 
first two years and duration of the inter-relapse inter-
val can also be valuable indicators8-11. Although the 
position on the influence of relapses on the progression 
of the disease is controversial, it is unquestionable that 
MS ultimately results in an unsustainable progressive 
phase with permanent disability of the patient12. The 
dual concept of the pathogenesis of MS significantly 
determines the start of treatment.
When discussing the treatment of MS, it is im-
portant to always emphasize the importance of tak-
ing an individual approach, for many reasons, i.e. the 
complexity of MS pathogenesis implies a high inter-
individual variability of the course of the disease; im-
munomodulation drugs have varying mechanisms of 
activity with high variability of therapeutic response; 
and there is a multitude of treatment algorithms, and 
selecting the right one should be adapted to the needs 
of each individual patient.
No Evidence of Disease Activity (NEDA) – A 
New Goal of Multiple Sclerosis Treatment
Until recently, it was considered that MS was reg-
ulated to a satisfactory level with the achievement of 
reduction in the number of relapses, a reduced number 
of new lesions visible on magnetic resonance imaging 
Fig. 1. Untreated multiple sclerosis is a dev-
astating disease3.
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(MRI), and slowing progression of patient disability. 
Today, the bar for treatment goals has been raised 
substantially higher, and new treatments are expected 
to completely halt the activity of the disease and pre-
vent the emergence of patient disability, as only such 
a treatment outcome will result in complete wellbeing 
of the patient.
The course of MS has changed since the advent 
of disease-modifying agents. These new drugs pro-
vide many benefits for patients, including fewer and 
less severe relapses, better recovery after relapses, pre-
vented or postponed progression of disability, reduced 
accumulation of disease burden or decreased brain le-
sion activity, and improved quality of life, cognitive 
functioning or less fatigue. This has led to evolving 
treatment goals, with wellbeing of the patient being 
now an important consideration in the therapeutic 
contract (Fig. 2).
No evidence of disease activity (NEDA) was first 
reported as a concept in 200913. This new treatment 
goal implies a state of complete absence of disease ac-
tivity, and represents a new concept in the treatment 
of MS, in which the imperative becomes ‘zero toler-





 -enhancing (GAD) lesions on annual MRI
No evidence of disease activity may become a 
key outcome measure of disease-modifying therapy 
(DMT) for MS patients, as well as a potential treat-
to-target goal, according to a new study. Up to 40% 
of patients achieve NEDA in 2 years with currently 
available drugs, but disability progression may be con-
founded by previous injury (Fig. 3)14.
Treating to target requires individualized planning 
of treatments and assessment in each patient, taking 
into account severity, recovery from relapses and le-
sion characteristics. Unresolved issues in individual-
izing treatment include optimal definition of NEDA 
and breakthrough disease, incomplete assessment, 
and integration of NEDA with treatment risks.
Research has shown that the share of NEDA 
patients in placebo controlled studies is consistently 
higher in patients receiving therapy than those on 
placebo after two years of monitoring. The exception 
was the CARE MS II study, in which alemtuzumab 
showed to be superior in relation to interferon beta 1a 
s.c. (Rebif) as the active comparator13 (Fig. 3).
Predictivity of Treatment Response
One of the greatest challenges in the treatment of 
patients with MS is the ability to predict treatment 
outcome. Response to treatment is highly heteroge-
neous among MS patients and therefore predictors of 
response to treatment are needed to optimize patient 
management. 
Which patients will be responders, and which will 
be non-responders? The assumption is that 20% of 
100 treated patients will have an optimal treatment 
response (as responders), 40% will have a suboptimal 
treatment response (partial responders), and 40% will 
have an unsatisfactory treatment response (non-re-
sponders) (Fig. 4).
Can we identify subgroups of patients who show 
different treatment effects? Clinical, MRI and bio-
logical parameters can all define the predictivity of 
response to treatment. A later age at onset, lower dis-
ability and lower number of GAD lesions at baseline 
MRI were predictors of treatment efficacy.
Early detection of nonresponders, i.e. patients 
without a satisfactory treatment response to the ad-
ministered treatment, in which the disease shows an 
increased level of activity, is very important in order to 
begin another type of treatment for those patients that 
will prove more effective (Fig. 5).Fig. 2. Treatment goals are evolving in multiple sclerosis.
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A later age at onset, lower disability and lower 
number of GAD lesions at baseline MRI were pre-
dictors of treatment efficacy15. However, it is not clear 
whether these parameters are really predictors of 
treatment response or prognostic factors. The risk of 
disability is greater in patients with increased MRI 
activity16,17. Brain atrophy measurement is not always 
a reliable measure, due to technical difficulties and 
bias during the acquisition and data analysis phases18. 
Clinical evaluation and MRI studies together could 
be more useful in defining the prognosis (Fig. 6). 
Brain Atrophy in Multiple Sclerosis – The Iceberg 
Analogy
Multiple sclerosis is usually referred to as an ‘ice-
berg disease’. There are research notes looking at the 
difference between clinical and subclinical MS re-
lapses that refer to them as MS icebergs. Visible dam-
age, such as relapse and clinical progression, is just the 
tip of the iceberg, while the ‘invisible’ damage, such as 
brain atrophy, is much more dangerous, as it can sneak 
up and cause patient disability.
Fig. 3. No evidence of disease activity (NEDA) status 
in patients with relapsing-remitting multiple sclerosis 
(RRMS) over two years.
Fig. 4. Out of 100 multiple sclerosis patients: who are re-
sponders?
Fig. 5. Responders versus non-responders.
Brain atrophy is a relevant surrogate marker of 
disease progression in MS because it represents the 
net effect of various pathological processes leading to 
brain tissue loss. It has been shown to correlate with 
cognitive impairment, EDSS and quality of life20-22. 
Brain atrophy seems to be a widespread process that is 
present in all stages of MS, even it can be seen as early 
as a clinically isolated syndrome23,24. Several studies 
have demonstrated that, on average, brain volume 
decreases by 0.7%-1% yearly in patients with MS25, 
which is approximately three-fold the rate in normal 
controls. Although both gray matter and white mat-
ter undergo atrophy, it has been suggested that loss 
of gray matter is a more sensitive marker of the neu-
rodegenerative process in MS than whole brain atro-
phy26. Furthermore, some in vivo data have suggested 
that the rate of gray matter volume loss accelerates as 
the disease progresses27. Gray matter volume appears 
to be a very clinically meaningful MRI metric; a re-
cent multicenter study in 977 patients at all stages of 
MS found gray matter volume to be a better predictor 
of disability and cognitive impairment, as measured 
by the EDSS and paced auditory serial addition test, 
respectively, than white matter volume or white mat-
ter lesions28. Similarly, gray matter volume correlated 
Acta Clin Croat,  Vol. 55,   No. 1,  2016 129
Ines Lazibat et al. Innovative therapies redefine treatment goals in multiple sclerosis
better with quality-of-life measures than white matter 
or whole brain volume21.
The ideal method for measuring brain volume 
loss in MS has not been determined. Segmentation-
based methods include the commonly used brain 
parenchymal fraction (BPF) and its variants, index 
of brain atrophy and whole brain ratio. BPF is de-
fined as the brain parenchymal volume divided by 
the volume within the surface of the brain. The BPF 
uses an algorithm to detect the outer surface of the 
brain and the amount of brain tissue within that 
outer surface, essentially subtracting out (segment-
ing out) the ventricular cerebrospinal fluid volumes. 
BPF has been shown to correlate moderately well 
with disability29.
Therapies that in clinical trials have shown a posi-
tive effect on reducing the rate of brain volume loss are 
natalizumab, fingolimod and alemtuzumab.
Natalizumab (NTZ) treatment significantly de-
creases cortical lesion accumulation and cortical at-
rophy progression in severe RRMS30. Investigation 
of atrophy data from a pivotal natalizumab trial has 
demonstrated an increased rate of volume loss com-
pared to placebo after the first year of therapy. It was 
considered to probably be due to a pseudoatrophy ef-
fect. Early brain volume loss during natalizumab ther-
apy is mainly due to white matter fraction (WMF) vol-
ume loss and it is related to the inflammatory activity 
present at therapy initiation. The pseudoatrophy effect 
is mostly due to white matter volume changes31 and it 
has been held responsible for the lack of net impact of 
natalizumab on brain volume outcomes in 2-year tri-
als, but no data are available beyond 24 months32.
Fingolimod (FGL) is the only oral therapy with a 
consistent, early and held on reducing the loss of brain 
volume (brain volume loss, BVL). Consistent effect 
of fingolimod to reduce BVL was demonstrated in 
three controlled phase 3 clinical trials33-36. Improve-
ments in outcomes related to cognition and BVL 
occurred within 6 months of fingolimod treatment 
initiation37,38.
Alemtuzumab (AZB) is the first and currently only 
MS therapy to demonstrate sustained improvement in 
preexisting disability versus an active comparator (in-
terferon beta 1a s.c.)13.
Treatment Strategy
The selection of an optimal treatment for MS is 
becoming an even greater challenge considering the 
growing number of new treatments available (Fig. 7).
The existing immunomodulation drugs (DMTs) 
have been proven to have only partial benefits in con-
trolling the progression of the disease, primarily by 
reducing the inflammation component. However, 
new treatments are offering to provide protection 
against BVL, which is of critical importance, as brain 
atrophy is today considered one of the most significant 
Fig. 6. Monitoring algorithm for assessment 
of clinical response19. 
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preindicators of future patient disability.
In line with the phrase ‘time is brain’, the treat-
ment of MS should begin early and it should be ef-
fective, as it is only possible to prevent conversion to 
the secondary progressive form of the disease that is 
marked by permanent disability through an early start 
to treatment.
Early treatment can delay relapses, disability, and 
BVL at long term. The case for early treatment is 
based on the ‘window of opportunity’ to prevent irre-
versible axonal damage. Early treatment will prevent 
the irreversible damage to the nervous system, which 
occurs very early and is (at least partially) related to 
inflammation in MS. It is also well known that the 
early course of the disease influences long term out-
comes. Immunomodulatory treatments can reduce the 
inflammation that predominates in the early phases 
of the disease, and patients with greater clinical ac-
tivity during their first year of treatment were at an 
increased risk of continuing with relapse and/or sus-
tained disability in the next two years39. Data from 
several clinical trials show that treatments for MS are 
more effective in the relapsing remitting phase than in 
the progressive phase of the disease40.
The traditional approach to treating MS implies 
commencing with a treatment of moderate efficacy, 
and in the case of unsatisfactory treatment response 
and persistence of active disease, a shift is made to the 
high and very high efficacy treatments.
However, it is important to stress that the high 
and very high efficacy treatments can also be the first 
choice treatment for patients with very active or rap-
idly progressing forms of the disease (Figs. 8 and 9).
Escalation treatment and induction treatment are 
two different algorithms in the treatment of MS. In 
escalation treatment, the safety profile of the treat-
ment is the top priority, whereas in induction treat-
ment the priority is efficacy and prompt halting of dis-
ease progression, even with increased treatment risk. 
Therefore, induction treatment is primarily intended 
for patients with very active and particularly rapidly 
progressing forms of the disease, who are threatened 
with rapid development of disability.
The choice of initial agent is influenced by fac-
tors relating to the agents themselves, the severity of 
the onset of the patient’s disease, and patient-specific 
factors such as medical comorbidities, reproductive 
status, and tolerance for risk. The decision must be 
based on careful consideration by the physician and 
discussion with the patient, taking many potential is-
sues into account and realizing in some cases there is 
no clear ‘best’ choice42. MS patients are now active 
players in the decision-making process; patients are 
having ever greater input into the decision making 
process surrounding their disease management. Their 
perception of the disease and the treatment response 
is a key component of MS management.
Timing of therapy for all currently available MS 
DMTs relates to the prevention of acute inflamma-
tion and relapse, including prevention of development 
of new lesions on MRI. Ultimately, the true goal is to 
prevent the development of disability, including long 
term disability related to progressive disease, as de-
scribed above. Starting DMT early in the MS disease 
course has been shown to have a beneficial effect on 
relapse prevention, and appears to curtail the atrophy 
Fig. 7. Treatment complexity. 
Fig. 8. Traditional approach to multiple sclerosis treat-
ment41. 
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and neurodegenerative changes that are now known 
to begin at disease onset42.
New treatments are more innovative and likely 
one step closer to an ideal treatment that implies not 
only absence of any disease activity, but also maxi-
Fig. 9. Algorithm for 
treatment of relapsing 
multiple sclerosis.
Fig. 10. The ideal multiple sclerosis therapy.
Fig. 10. The ideal 
multiple sclerosis therapy
mum safety, excellent tolerance, maintenance of work 
capabilities and quality of life for the patient. Once 
this level of treatment excellence has been achieved, 
we may be able to speak of having a possible cure for 
MS (Fig. 10).
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Sažetak
INOVATIVNE TERAPIJE REDEFINIRAJU TERAPIJSKE CILJEVE U MULTIPLOJ SKLEROZI
I. Lazibat, R. Kuzmanić Šamija i K. Rotim
Liječenje multiple skleroze (MS) postaje sve složenije, naročito zbog rastućeg broja dostupnih terapija za relapsni oblik MS. Sve 
bolje razumijevanje degenerativnog aspekta patogeneze MS redefinira terapijske ciljeve i stvara nove terapijske strategije. Dosadašnji 
imunomodulacijski lijekovi (disease-modifying therapies, DMTs) u terapiji MS pokazuju samo djelomičnu korist u kontroli progresije 
bolesti, prvenstveno smanjujući upalnu komponentu. Međutim, nove terapije u MS pokazuju djelotvoran učinak na odgađanje pro-
gresije bolesti štiteći od atrofije mozga koja se smatra najvažnijim predskazateljem budućeg invaliditeta bolesnika. Pozitivan utjecaj na 
smanjenje atrofije mozga ukazuje na potencijalno neuroprotektivno ili čak neuroregenerativno djelovanje novih terapija, što predstavlja 
korak naprijed u liječenju MS.
Ključne riječi: Multipla skleroza – terapija; Multipla skleroza, recidivirajuće-remitentna – farmakoterapija; Imunosupresivna sredstva – 
terapijska primjena; Ishod liječenja
